The American Lung Association (ALA) is taking steps to address the stark underrepresentation of Latinos in lung cancer clinical trials, a disparity that could have far-reaching implications for health outcomes in this community. Despite comprising approximately 19% of the U.S. population, Latinos account for a mere 1% of clinical trial participants, according to the ALA.
To combat this issue, the ALA is expanding its “Awareness, Trust and Action” campaign to Port St. Lucie, Florida. The initiative aims to increase Latino participation in clinical trials, which are crucial for advancing lung cancer research and improving survival rates. Dr. Frank J. Eidelman, a member of the Lung Association’s South Florida Board, emphasized the importance of this effort, stating, “Hispanic participants are greatly underrepresented, and this campaign brings awareness to this important issue.”
The campaign’s objectives include raising awareness about clinical trials as a treatment option, addressing misconceptions and mistrust surrounding these trials, and empowering Latinos to discuss clinical trial opportunities with their doctors. The ALA’s research revealed a need for clear, culturally appropriate education about clinical trials within the Latino community.
While lung cancer incidence and mortality rates among Latinos are about half those of non-Hispanic whites, an estimated 11,800 Latinos were diagnosed with lung cancer from 2021 to 2023. This underscores the importance of diverse representation in clinical trials to ensure that medical advancements benefit all populations equally.
Dr. Eidelman highlighted the dual benefits of increased participation, noting, “Not only do trial participants benefit from the latest science and treatments, but researchers can better understand how lung cancer treatments work in different populations.” By addressing this disparity, the ALA hopes to improve lung cancer care and outcomes for Latino communities across the United States.
See: “Improving Lung Cancer Outcomes in Latinos Through Clinical Trial Participation” (October 25, 2024)
